Download pdf
Application and development of TCR-T in tumor therapy
- 1 Peking University
* Author to whom correspondence should be addressed.
Abstract
As cancer has gradually become the world's deadliest long-term disease, the impact on the public health has been devastating. Especially the Melanoma which is a cancer with a very high malignant and a high fatality rate. With the emergence of adoptive cell therapy(ACT) based on T Cell Receptor-Gene Engineered T Cells (TCR-T), good results have been obtained in scientific research and clinical fields for a variety of malignant tumors. As TCR-T continues to enter the clinic, the FDA also has approved the first case of TCR-T in 2022, and more and more basic researches and clinical trial projects based on TCR-T are gradually being carried out. However, TCR-T therapy still has some defects, such as non-tumor tissue damage caused by off-target effect and insufficient affinity with tumor tissue. Therefore, the affinity and anti-tumor effectiveness of TCR-T should be improved in multiple aspects, and multi-field cooperation should be carried out to promote the development of basic research, a number of products should be introduced into the clinic, and the intervention of economic means to improve the accessibility of TCR-T. Not only brings the Gospel of cure to patients in the field of solid tumors, but also produces innovation in the field of non-solid tumors.
Keywords
T cell receptor-gene engineered T cells, adoptive cell therapy, tumor therapy
[1]. Aparicio C Belver M Enríquez L et al 2021 Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor CAR -T Cells International journal of molecular sciences 22 21 11781
[2]. Wang Z & Cao Y J 2020 Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research Frontiers in immunology 11 176
[3]. Yee C Thompson J A Byrd D et al 2002 Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence migration and antitumor effect of transferred T cells Proceedings of the National Academy of Sciences of the United States of America 99 25 16168–16173
[4]. Hughes M S Yu Y Y Dudley M E et al 2005 Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions Human gene therapy 16 4 457–472
[5]. Malecek K Grigoryan A Zhong S et al 2014 Specific increase in potency via structure-based design of a TCR Journal of immunology Baltimore Md: 1950 193 5 2587–2599
[6]. Lu Y C Zheng Z Robbins P F Tran E et al 2018 An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors Molecular therapy: the journal of the American Society of Gene Therapy 26 2 379–389
[7]. Lu Y C Zheng Z Robbins P F et al 2018 An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors Molecular therapy: the journal of the American Society of Gene Therapy 26 2 379–389
[8]. Damato B E Dukes J Goodall H & Carvajal R D 2019 Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma Cancers 11 7 971
[9]. Shafer P Kelly L M & Hoyos V 2022 Cancer Therapy With TCR-Engineered T Cells: Current Strategies Challenges and Prospects Frontiers in immunology 13 835762
[10]. Liu Y Yan X Zhang F et al 2022 TCR-T Immunotherapy: The Challenges and Solutions Frontiers in oncology 11 794183
[11]. Gladow M Uckert W & Blankenstein T 2004 Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors European journal of immunology 34 7 1882–1891
Cite this article
Feng,H. (2024). Application and development of TCR-T in tumor therapy . Theoretical and Natural Science,48,22-27.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).